BioLineRx is trading at $3.25, up 16.91%, with the catalyst unconfirmed.
- The stock rose from its August 6 close of $2.79; searches found no clear company-specific announcement released on August 7, 2026.
- The next reported earnings date is August 13, 2026; the latest identifiable company news was July 8 preclinical GLIX1 data, unlikely to directly explain this morning’s move.
- Broader futures are modestly higher, but that backdrop alone does not clearly explain the move.